Atsena Therapeutics Overview

Key information, insights, contact details, and team at Atsena Therapeutics.

Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases. Their clinical programs include therapies for X-linked retinoschisis (XLRS) and GUCY2D-associated Leber congenital amaurosis (LCA1). Atsena utilizes an adeno-associated virus (AAV) technology platform, including a novelspreading capsid (AAV.SPR), to target specific retinal conditions. Their ongoing research aims to prevent blindness caused by genetic mutations and is powered by their innovative approach to ocular gene therapy.

Biotechnology Health Care Therapeutics

$150M

Latest Funding

Series C

Latest Funding Stage

2025-04-04

Funding Date

30

Employees

United States

Location

Durham, North Carolina

City & State

Investment Thesis

No thesis information available yet.

Key Contacts
Unlock Contact Information

Upgrade to access founder details

Upgrade Now

Team Members

(Showing 0 of )

Founding Story

No founding story information available yet.

Product

No product analysis information available yet.

Market

No market analysis information available yet.

Competition

No competitive analysis information available yet.

Business Model

No business model analysis information available yet.

Similar Companies

Trellis Health
Trellis Health Logo

Trellis Health is a healthcare clinician trial that delivers personalized care for women and families. The clinicians Trellis bridges critical gaps in women’s healthcare with intuitive tools that simplify health management over time.

AMT Medical
AMT Medical Logo

AMT Medical BV has developed a minimal invasive medical device for heart bypass surgery. The AMT Heart Bypass System is based on the ELANA bypass, technology invented by neurosurgeon Prof. Dr. C.A.F. T

Glycomine
Glycomine  Logo

Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options.

Chapter
Chapter  Logo

Chapter develops a Medicare navigation platform that offers advisory services to help seniors select health coverage. The company ensures consumers get the right coverage for their needs at the lowest possible price. Its Medicare navigation platform aligns incentives between medicare advisors and consumers by considering all options and makingrecommendations independent from economic relationships.

Traction

No traction analysis information available yet.

Valuation

No valuation analysis information available yet.

Key Opportunities

No key opportunities information available yet.

Key Risks

No key risks information available yet.